Targeting Donor Dendritic Cell Subsets Prevents Lethal Gut Graft-Versus-Host Disease in Mice

Refining Prophylaxis for Gastrointestinal Graft-Versus-Host Disease

Acute graft-versus-host disease remains a primary obstacle to successful allogeneic hematopoietic stem cell transplantation, as the required lifelong immunosuppression can negatively affect long-term graft and patient survival [1]. While cell-based therapies such as mesenchymal stromal cells (multipotent cells that alter cytokine profiles to induce an anti-inflammatory phenotype) have been explored, the risk of treatment-related toxicity and infection remains a clinical priority [2, 3]. In a phase I/IIa clinical trial involving 13 patients with hematologic malignancies, a single infusion of donor early apoptotic cells at doses of 140 or 210 × 10^6 cells/kg resulted in a 0% incidence of grade II to IV acute graft-versus-host disease, compared to a 23% incidence across all dose groups [4]. Gastrointestinal involvement is particularly severe, as dysregulated production of interleukin-6 (a cytokine that stimulates acute phase responses) drives rapid tissue damage and early transplant mortality [5, 6]. New research indicates that donor XCR1+ conventional dendritic cells (specialized antigen-presenting cells) are essential for initiating Th1-mediated gut damage, while CD11b+ dendritic cells drive Th17-dependent inflammation [6]. Identifying these distinct cellular mechanisms is critical for developing targeted prophylactic regimens that preserve the delicate balance between immune tolerance and antimicrobial immunity [7, 6].

Mapping Dendritic Cell Dynamics in the Post-Transplant Gut

Acute graft-versus-host disease of the gastrointestinal tract remains a primary cause of early mortality following bone marrow transplantation. This lethal complication is driven by local antigen presentation, a process where immune cells display foreign peptides to T cells, leading to subsequent T-cell expansion within the gut environment. Understanding the specific cellular drivers of this process is essential for clinicians managing post-transplant complications, as the intestinal lining is particularly vulnerable to donor-derived immune attack. To clarify this mechanism, researchers focused on how different subsets of donor dendritic cells (specialized white blood cells that bridge innate and adaptive immunity) orchestrate this destructive response. The study observed distinct spatial distributions of donor dendritic cell subsets depending on the presence or absence of disease. In the ileum of bone marrow transplant recipients who did not develop graft-versus-host disease, donor plasmacytoid dendritic cells (a subset of immune cells known for producing type I interferons) were prominent. However, these donor plasmacytoid dendritic cells were largely absent in the gut during active graft-versus-host disease, suggesting they may play a role in maintaining intestinal homeostasis or are rapidly depleted during the inflammatory process. Conversely, the researchers identified a significant accumulation of donor XCR1+ conventional dendritic cells, a specialized lineage efficient at cross-presenting antigens to CD8+ T cells. These donor XCR1+ conventional dendritic cells were dramatically increased in the mesenteric lymph nodes (the lymph nodes that drain the intestines) of bone marrow transplant recipients suffering from active disease. This localized increase suggests that these specific conventional dendritic cells are the primary drivers of the alloantigen-specific T-cell response that characterizes gastrointestinal graft-versus-host disease, providing a specific cellular target for preventing transplant-related mortality.

Selective Depletion of XCR1+ Cells Attenuates Lethal Inflammation

To isolate the specific contributions of different immune subsets to intestinal injury, the researchers utilized genetically modified murine models (Xcr1-DTR and Clec4c-DTR mice) that allow for the highly efficient, targeted depletion of specific cell lines using diphtheria toxin. Through these models, the study demonstrated that the deletion of donor XCR1+ conventional dendritic cells attenuated lethal graft-versus-host disease, significantly improving survival outcomes. In stark contrast, the deletion of donor plasmacytoid dendritic cells did not attenuate lethal graft-versus-host disease, indicating that this specific subset is not a viable therapeutic target for preventing the systemic inflammatory response following bone marrow transplantation. The therapeutic benefit observed with the removal of XCR1+ cells is directly linked to their role in initiating the donor immune assault. The researchers found that XCR1+ conventional dendritic cell deletion depleted most conventional dendritic cells presenting alloantigen (the recipient proteins that donor T cells recognize as foreign). This reduction in antigen presentation had profound downstream effects on T-cell behavior. Specifically, the loss of these dendritic cells inhibited the expression of α4β7, a specialized cellular adhesion molecule that directs T cells to migrate specifically to the gastrointestinal tract. Furthermore, it inhibited the expansion of alloantigen-specific donor Th1 cells in the gut. Collectively, these data indicate that plasmacytoid dendritic cells have a limited role in the induction of gut graft-versus-host disease, while XCR1+ conventional dendritic cells serve as the primary orchestrators of Th1-mediated intestinal damage, raising the prospect that future prophylactic therapies could selectively target this subset to spare the gut.

Enzymatic Inhibition Targets the Th17-Mediated Pathway

Beyond the structural depletion of dendritic cell subsets, the researchers investigated the metabolic pathways that drive intestinal inflammation. Aldehyde dehydrogenase 1A (ALDH1A) expression by conventional dendritic cells is known to modulate graft-versus-host disease, serving as a key enzymatic regulator of immune signaling. To test the therapeutic potential of targeting this pathway, the study examined the effect of a pan-ALDH1 inhibitor, WIN18,446, on the dendritic cell axis. The researchers found that WIN18,446 administration improved survival in the study models, suggesting that pharmacological inhibition of this enzyme can mitigate the lethal effects of the donor immune response. Further analysis revealed that the clinical benefits of this enzymatic blockade were highly specific. The survival effects of WIN18,446 were ALDH1A1-specific, indicating that the ALDH1A1 isoform (a specific variant of the aldehyde dehydrogenase enzyme) is the primary driver of the observed pathology. Notably, the effects of WIN18,446 were mediated by the inhibition of CD11b+ conventional dendritic cells rather than XCR1+ conventional dendritic cells. This distinction is critical for clinical targeting, as it demonstrates that different dendritic cell subsets rely on distinct metabolic signatures to promote inflammation. The inhibition of the CD11b+ subset, a group of myeloid-derived cells that typically promote inflammatory responses, resulted in a significant shift in the local immune environment. Specifically, the inhibition of CD11b+ conventional dendritic cells inhibited alloantigen-specific Th17 cell differentiation in the gut, blocking the development of pro-inflammatory T helper cells that produce interleukin-17. These findings establish that donor XCR1+ and CD11b+ conventional dendritic cells play differential and dominant roles in controlling Th1 and Th17 mediated gut graft-versus-host disease, respectively. While XCR1+ cells drive the Th1 response, the CD11b+ subset is the primary orchestrator of the Th17-mediated pathway. For practicing hematologists and oncologists, these insights provide two distinct, targetable cellular pathways for preventing lethal intestinal damage after bone marrow transplantation.

References

1. Annamalai C, Kute V, Sheridan C, Halawa A. Hematopoietic cell-based and non-hematopoietic cell-based strategies for immune tolerance induction in living-donor renal transplantation: A systematic review.. Transplantation reviews (Orlando, Fla.). 2023. doi:10.1016/j.trre.2023.100792

2. Lalu MM, McIntyre L, Pugliese C, et al. Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE. 2012. doi:10.1371/journal.pone.0047559

3. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2004. doi:10.1182/blood-2004-04-1559

4. Mevorach D, Zuckerman T, Reiner I, et al. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014. doi:10.1016/j.bbmt.2013.10.010

5. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology. 2014. doi:10.1101/cshperspect.a016295

6. Takahashi S, Inoue T, Ensbey KS, et al. Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1- and Th17-dependent GVHD within the gastrointestinal tract.. Blood. 2026. doi:10.1182/blood.2025029431

7. Keir M, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology. 2008. doi:10.1146/annurev.immunol.26.021607.090331